14-day Premium Trial Subscription Try For FreeTry Free

Latest Data & Signals Issued

Signal Type Signal Value Data
Score -3.605 7 days ( -1.77 % )
Last Price $1.15 6.48 %
High/ Low $1.08 - $1.16 24.07%
Chg 7 Days -1.29 % $1.17 $1.15
Chg 30 Days -21.77 % $1.47 $1.15
Chg 12 mos -25.32 % $1.54 $1.15
Trend - 3 mos 38.71 % Width: 49.31 %
Trend - 12 mos -40.43 % Width: 711.97 %
Pred. range - 3 mos $1.51 - $2.25 31.15 % - 95.82 %
Pred. range - 12 mos $0.114 - $0.92 -90.11 % - -19.67 %
Short MA avg 3 mos Buy May 02, 2024 - 2 days
Long MA avg 3 mos Sell Apr 24, 2024 - 8 days
Short/Long MA avg 3 mos Sell Apr 26, 2024 - 6 days
Short MA avg 12 mos Buy Apr 19, 2024 - 11 days
Long MA avg 12 mos Buy Feb 02, 2024 - 64 days
Short/Long MA avg 12 mos Buy Feb 14, 2024 - 56 days
Pivot Short Sell Apr 04, 2024 - 22 days
Bollinger Buy Mar 14, 2024 - 36 days
MACD Sell No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!

About X4 Pharmaceuticals Inc.

X4 Pharmaceuticals. X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and my... XFOR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT